Parkedale Fluogen
Executive Summary
Production resumes at King's Parkedale facility April 13 after the company provides written certification to FDA that it has completed corrective action for cGMP deviations. Resumption of distribution of the flu vaccine will depend on FDA reinspection of Parkedale's facilities (1"The Pink Sheet" March 20, p. 27)
You may also be interested in...
Parkedale Turns To Consultants After FDA Halts Fluogen Production
Parkedale Pharmaceuticals is drawing on advice from regulatory consultants The Biologics Consulting Group and regulatory legal counsel Arnold and Porter in "evaluating strategies pertaining to Fluogen," the company said.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials